Boston-based Rhythm has gone back to the venture well to draw up a fresh $40 million in backing from some A-list investors to fuel a mid-stage program for rare genetic disorders linked with a lethal level of obesity.
As the Ebola outbreak continues to wane in West Africa, vaccines experts are combing over what went wrong--and right--with the development of vaccine candidates against the virus.
Senseonics, the maker of an implantable continuous glucose monitor device, has picked up $20 million in venture funding, according to a regulatory filing.
There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.
A new oncology compound from AbbVie and Roche's Genentech division cleared its primary hurdle in a Phase II blood cancer trial, opening the door to an FDA filing by year's end.
Helius Medical Technologies is set to begin a Phase III clinical trial with the U.S. Army Medical Research and Materiel Command for its Portable Neuromodulation Stimulator (PoNS), which is designed to treat balance disorder for patients with traumatic brain injury.
Less than three months after seeing its share price get crushed in the panic following a late-stage failure of its lead drug, Cambridge, MA-based Eleven Biotherapeutics is rolling the dice in a last-ditch effort to produce approval-worthy Phase III data.
Liquid biopsy player Biocept is teaming up with the University of California, Irvine, to evaluate blood-based biomarkers (as opposed to tissue-based ones) in patients with metastatic cancers. The duo hopes to validate liquid biopsies as a treatment guide for precision medicines and develop a system for monitoring tumor mutations to identify signs of resistance to therapy.
Google is divvying up its composite parts, becoming, depending on whom you ask, the new Berkshire Hathaway, the next General Electric or something heretofore never seen. But the move could have mixed implications for Google's nascent but growing life sciences empire.
Clovis Oncology is planning to test whether its oral lung cancer drug can work in tandem with a closely watched injectable treatment from Roche's Genentech division, hoping to expand the potential for its breakthrough-designated therapy.